JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes

Patients with essential thrombocythemia may carry JAK2 (V617F), an MPL substitution, or a calreticulin gene (CALR) mutation. We studied biologic and clinical features of essential thrombocythemia according to JAK2 or CALR mutation status and in relation to those of polycythemia vera. The mutant alle...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Rumi, Elisa, Pietra, Daniela, Ferretti, Virginia, Klampfl, Thorsten, Harutyunyan, Ashot S., Milosevic, Jelena D., Them, Nicole C. C., Berg, Tiina, Elena, Chiara, Casetti, Ilaria C., Milanesi, Chiara, Sant’Antonio, Emanuela, Bellini, Marta, Fugazza, Elena, Renna, Maria C., Boveri, Emanuela, Astori, Cesare, Pascutto, Cristiana, Kralovics, Robert, Cazzola, Mario
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2014
Konular:
Myeloid Neoplasia
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3945864/
https://ncbi.nlm.nih.gov/pubmed/24366362
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-11-539098
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller